CD 19×CD3 specific polypeptides and uses thereof

Details CD 19×CD3 specific polypeptides and uses thereof CD 19×CD3 specific polypeptides and uses thereof

2006-09-26

2006-09-26

Helms, Larry R. (Department: 4241)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S134100, C424S136100, C530S387300, C530S388150, C530S388850

Reexamination Certificate

active

07112324

ABSTRACT:
Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described, In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.

REFERENCES:
patent: 5239062 (1993-08-01), Blattler et al.
patent: 195 31 348 (1997-02-01), None
patent: 0 505 908 (1992-09-01), None
patent: 91/09968 (1991-07-01), None
patent: 95/11922 (1995-05-01), None
patent: 96/36360 (1996-11-01), None
Jonge et al Cancer Immunol immunother 45:162-165, 1997.
Rudikoff et al PNAS 79:1979, 1982.
Mack et al PNAS 92:7021-25, 1995.
Bohlen et al Blood 82:1803-12, 1993.
Sompuram et al., The Journal of Immunology 156:1071-81, 1996.
Olsen et al., Hybridoma and Hybridomics 22:65, 2003.
H. Bohlen et al., “Treatment of EB-Virus Induced B-Cell LCL in SCID-HU Mice Using CD3×CD19 Bispecific and CD28 Antibodies.”, Proceedings of the American Association for Cancer Research, vol. 35, Mar., 1994, p. 510, XP-002076122, abstract.
Jan De Jonge et al., “Bispecific antibody treatment of murine B cell lymphoma.”, Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 162-165, XP-002076120, Springer-Verlag, 1997.
Sergey M. Kipriyanov et al., “Bispecific CD3×CD19 Diabody for T-Cell-Mediated Lysis of Malignant Human B Cells.”, International Journal of Cancer, vol. 77, Aug. 31, 1998, pp. 763-772, XP-002115487, Wiley-Liss, Inc., 1998.
P. Kufer et al., “Construction and bilogical activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.”, Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 193-197, XP-002076121, Springer-Verlag, 1997.
Anja Schroder et al., “A Recombinant Bispecific Single Chain Antibody CD19×CD3 Induced Rapid B Cell Lymphoma-Directed Cytotoxicity of Unstimulated Human T Cells.”, 40thAnnual Meeting Of The American Society Of Hematology Miami Beach, Florida, Dec. 4-8, 1998, XP-002115457, abstract.
“National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphomas, Summary and Description of a Working Formulation for Clinical Usage.”, Cancer, vol. 49, pp. 2112-2135, 1982, (Exhibit 1).
Harald Stein et al., “Die neue WHO-Klassifikation der malignen Lymphome.”, Deutsches Arzteblatt, vol. 96, pp. C-2302-C-2309, Dec., 1999, including English language summary, (Exhibit 2).
Parveen Kumar et al., 3rdEdition, Clinical Medicine, pp. 369-370, Bailliere Tindall, (Exhibit 3).
Jan De Jonge et al., “Production and Characterization of Bispecific Single-Chain Antibody Fragments.”, Molecular Immunology, vol. 32, No. 17/18, pp. 1405-1412, 1995, (Exhibit 4).
Jan De Jonge et al., “In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3× Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model1.”, The Journal of Immunology, vol. 161, pp. 1454-1461, 1998, (Exhibit 5).
Matthias Mack et al., “Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3.”, Proceedings of the National Academy of Science, vol. 92, pp. 7021-7025, 1995, (Exhibit 6).
Anderson, P. M., et al., G19.4(αCD3)×B43(αCD19) Monoclonal Antibody Heteroconjugate Triggers CD19 Antigen-Specific Lysis of t(4;11) Acute Lymphoblastic Leukemia Cells by Activated CD3 Antigen-Positive Cytotoxic T Cells, Blood, vol. 80, No. 11, pp. 2826-2834 (1992).
Bohlen, H., et al., “Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies”, Cancer Research, vol. 53, pp. 4310-4314 (1993).
Haagen, I., et al., “Killing of Autologous B-Lineage Malignancy Using CD3×CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma”, Blood, vol. 84, No. pp. 556-563 (1994).
Haagen, I., et al., “Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic”, Cancer Immunol. Immunother, vol. 39, pp. 391-396 (1994).
De Gast, G. C., et al., “Clinical Experience with CD3×CD 19 Bispecific Antibodies in Patients with B Cell Malignancies”, J. Hema., vol. 4, pp. 433-437 (1995).
Weiner, G. J., et al., “Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy”, Leukemia and Lymphoma, vol. 16, pp. 199-207 (1995).
Haagen, I., “Performance of CD3×CD19 Bispecific Monoclonal Antibodies in B Cell Malignancy”, Leukemia and Lymphoma, vol. 19, pp. 381-393 (1995).
Haagen, I., et al., “The Efficacy of CD3×CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2”, Blood, vol. 85, No. 11, pp. 3208-3212 (1995).
Mack, M., et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity”, Pro. Natl. Acad. Sci., vol. 92, pp. 7021-7025 (1995).
Kipriyanov, S. M., et al., “Bispecific diabody for lysis of human B-lineage leukemia cells”, The Fourteenth International Conf. on Adv. In the Application of Monoclonal Antibodies in Clinical Oncology, p. 29 Thira Santorini, Greece (May 5-7, 1997).
De Jonge J., et al., “Bispecific antibody treatment of murine B cell lymphoma”, Cancer Immunol. Immunother, vol. 45, pp. 162-165 (1997).
Kufer, P., et al., “Construction and biological activity of a recombinanat bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer”, Cancer Immunol. Immunother, vol. 45, pp. 193-197 (1997).
Kipriyanov, S. M., et al., “Bispecific CD3×CD 19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells”, Int. J. Cancer, vol. 77, pp. 763-772 (1998).
Edelstein, M.L., et al., “Gene Therapy Clinical Trials Worldwide: 1989-2004-An Overview”,J. Gene Med., vol. 6, pp. 597-605 (2004).
Reusch, U., et al., “Effect of Tetravalent Bispecific CD 19×CD3 Recombinant Antibody Construct and CD28 Costimulation of Lysis of Malignant B Cells from Patients with Chronic Lymphocytic Leukemia by Autologous T Cells”,Int. J. Cancer, vol. 112, pp. 509-518 (2004).
Loffler, A., et al., “A Recombinant Bispecfic Single-Chain Antibody, CD19×CD3, Induces Rapid and High Lymphoma-directed Cytotoxicity by Unstimulated T Lymphocytes”,Blood, vol. 95, No. 6, pp. 2098-2103 (2000).
Kipriyanov, S.M., et al., “Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics”,J. Mol. Biol., vol. 293, pp. 41-56 (1999).
Holliger, P., et al., “Diabodies: Small Bispecific Antibody Fragments”,Cancer Immunol. Immunother, vol. 45, pp. 128-130 (1997).
Pezzutto, A., et al., “CD19 Monoclonal Antibody HD37 Inhibits Anti-Immunoglobulin-induced B Cell Activation and Proliferation”,J. of Immunology, vol. 138, No. 9, pp. 2793-2799 (1997).
Csoka, M., et al., “Activation of T Cell Cytotoxicity Against Autologous Common Acute Lymphoblastic Leukemia (cALL) Blasts by CD3×CD19 Bispecific Antibody”,Leukemia, vol. 10, pp. 1765-1772 (1996).
Davis, B.M., et al., “Current Progress in the Gene Therapy of Cancer”,Current Opinion in Oncology, vol. 8, pp. 499-508

Affiliated with

Also associated with

Rating

CD 19×CD3 specific polypeptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CD 19×CD3 specific polypeptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD 19×CD3 specific polypeptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3540855